Piramal Pharma Ltd - 543635 - Audio Recording Of Conference Call On The Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March, 2023
Audio Recording of Conference Call on the financial results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023 Q4FY23 Quarterly & FY23 Annual Result Announced for Piramal Pharma Ltd.
Pharmaceuticals company Piramal Pharma announced Q4FY23 & FY23 results: Revenue from Operation grew by 2% YoY in Q4FY23 and 8% in FY23 EBITDA margin for Q4FY23 and FY23 was 17% and 12% respectively impacted by lower sales and higher operating expenses Successfully cleared multiple regulatory inspections and customer audits in FY23 New capabilities / capacity expansion gone live at Ahmedabad PDS, peptide facility (Turbhe, India) and Riverview (US) are witnessing good customer demand Rights Issue – DLOF filed with the SEBI, currently under review Nandini Piramal, Chairperson, Piramal Pharma said, “Over the recent years, Q4 has always been the strongest quarter for the Company in terms of revenue contribution and EBITDA margin. This year as well, we have seen a healthy pickup in our Q4 revenues and EBITDA margin compared to previous three quarters of the financial year. Our CDMO business, which had a challenging year, witnessed significant pickup in order bookings in Q4. Our Inhalation Anesthesia portfolio continues to see a healthy demand and hence we are expanding our capacities. Our India Consumer Healthcare business is delivering good growth driven by our power brands. We continue to maintain our quality track record with successful US FDA inspections – zero observations at Riverview and Digwal facilities, and EIR received for Lexington and Sellersville facilities. We believe in the potential of our businesses and our main focus over the next few months will be on capturing demand and executing them well, driving productivity through operational excellence and executing critical maintenance and growth capex.” Result PDF Piramal Pharma Ltd - 543635 - Compliance Under Regulation 23 (9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)
Compliance under Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) Piramal Pharma Ltd - 543635 - Intimation Of Annual General Meeting Of The Company
Intimation of Annual General meeting of the Company Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and Investor Presentation - Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2023 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor Presentation
Press Release and Investor Presentation - Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2023 Piramal Pharma Ltd - 543635 - Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March, 2023
Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2023 Piramal Pharma Ltd - 543635 - Board Meeting Outcome for Outcome Of Board Meeting - Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March, 2023
Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2023 Piramal Pharma Ltd - 543635 - Board Meeting Outcome for Outcome Of Board Meeting - Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March, 2023
Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2023